Category Archives: Cancer Institute

How Eric Lefkofsky and Tempus are Using Technology for Cancer Treatment

Tempus, a Chicago based healthcare startup that focuses on utilizing genomic sequencing to give doctors a better ability to customize their cancer treatment plan, recently announced an impressive $70 million in funding. The funding comes as part of an open series C funding round. The core investors in this funding round are New Enterprise Associates and Revolution Growth, along with Tempus founders who have contributed their own funds to every series of funding for Tempus so far.

Tempus was founded in 2015 by Eric Lefkofsky. Lefkofsky is a well known name in the tech world and has founded such entities as Groupon and Uptake Industries in the past. With the Series C funding round totaling $70 million, this brings total funding for healthcare startup Tempus to over $130 million. This level of funding comes after just a few short years; Tempus was founded in 2015.

Tempus is certainly a unicorn of the healthcare and tech startup worlds, with an estimated valuation of over $700 million after less than two years in existence and Eric’s lacrosse camp.

Lefkofsky is known as a disruptor in the technology industry. He is known for integrating the most modern trends in technology and digital mediums to design creative solutions for modern industry. He is an adjunct professor at the prestigious University of Chicago and is also a published author of the book Accelerated Disruption, which speaks to how we can better comprehend the true nature of innovation. He is also a Trustee of the Art Institute of Chicago, the Museum of Science and Industry and of Lurie Children’s Hospital of Chicago.

Tempus is focused on redefining how genomic data is used and categorized to give physicians access to more data which in turn gives them the ability to craft more customized cancer treatments. Tempus wants to create the world’s first ever streamlined operations system that houses all past data of cancer research and patient results. While a great deal of data is collected, there is currently no system that makes it simple for physicians to access data from other facilities and read full article.

With the influx of $70 million in funding, Tempus will be well on its way to accomplishing their goal.

Other Reference: http://lefkofskyfoundation.com/

Mikhail Blagosklonny is Spreading Awareness of the Practice of Oncology

An established professor of oncology at the Roswell Park Cancer Institute, Mikhail Blagosklonny’s studies lie primarily in the realm of cancer and aging. He earned an MD in internal medicine at the Medical University of St. Petersburg, where he also earned a Ph.D. in Experimental Medicine and Cardiology. In the New York Medical College, located in Valhalla, New York, Blagosklonny was appointed the associate professor of medicine. This opened doors for him to transfer from the college to serve as the senior scientist at the Ordway Research Institute and eventually he joined the Roswell Park Cancer Institute in the position of Professor of Oncology, as recent as 2009.

His experience is apparent in the handful of roles he’s worked in and has gained invaluable knowledge along his journey, which he now brings to the table in order to enrich the education of his students at the Ordway Research Institute. At the heart of his interests for research is Biogerontology, which is the study of the underlying details behind aging. The professor also teaches and actively researches in subjects including cancer, anti-aging drugs, and in methods that target cancer cells in order to prevent healthy cells from being affected. So, in essence, cancer prevention methods and medicines.

View: https://scholar.google.com/citations?user=REO9YogAAAAJ&hl=en

Aside from his role as Professor of Oncology, Mikhail Blagosklonny also holds a position as the editor-in-chief of Oncotarget and Cell Cycle and as such, serves also as the associate editor of cancer biology and therapy. Among his many positions as an oncology professional, he has also received the esteemed position on the editorial board for Cell Death and Differentiation. During his extensive studies, Mikhail has a strong belief in the drug Rapamycin, which is a popular drug used in treating cancer. He hypothesizes that it is a possible solution for use in life extension and has been deemed one of the more passionate oncologists in support of the drug Rapamycin. He has dedicated much of his time in researching the drug and its benefits in longevity treatment.

Mikhail Blagosklonny’s research into Rapamycin ranges from molecular biology studies to cellular to clinical investigations. It includes in large part tumor suppressors, ontogenesis, signal transduction, apoptosis, anticancer therapeutics, mitosis, cell cycle, and normal cells selective protection. As such, Mikhail is an avid writer on these subjects and writs about these topics, as well as other topics that interest him, such as aging hyperfunction theory, chemotherapeutic engineering, and cell cyclotherapy. Visit classroomvoices.org to read more about Mikhail.

Omar Boraie: Helping The Development Of Cancer Treatment Research

Omar Boraie is a man who has worked extremely hard for the betterment of society. His various philanthropic and professional endeavors have led to the incredible development of the city of New Brunswick, a place where the Boraie company first laid its roots. Continuing on his mission to help the community, Omar recently donated a total of $1.5 million towards the development and research of new treatments for combating cancer, reports patch.com.

Hailing from Egypt, Omar originally came to America to pursue a Ph. D in Chemistry. After completing his educational course, Omar decided to expand his family’s business into the city of New Brunswick and turn the then run downtown into a hub of residential excellence. Omar had a vision in mind for the development of the community of New Brunswick and implemented his goal in the most efficient way to make the city what it is today.

The pledge to donate $1.5 million was made as part of a ‘Chair Challenge’ started up by Rutgers University. The rules of the challenge were simple. In the end, the university will be receiving double the amount that was initially promised.

Omar’s donation was made with the aim of helping the universities genomic science department. The genomic science department of Rutgers University has been known to have made some of the most groundbreaking advances in the field of medical research. Most recently, the department has made revolutionary discoveries when it comes to genomic science which can extensively benefit patients in the treatment of cancer. With the new research in place, doctors who are treating patients with cancer now have the option to tailor the treatment for each patient, owing to the new technology to tackle the cancerous tumour from the genetic level. This research is proven to be extremely beneficial in the treatment of cancer and also for the development of cancer research.

In the past, he has repeatedly pledged for the development of research, in various medical fields. Omar has always aimed to make New Brunswick a city where healthcare is one of the top priorities. By pledging this amount to Rutgers University, Omar is paving the path for the development of medical institutions in New Brunswick and as well as the entire field of cancer research.